These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20213318)

  • 41. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
    Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.
    Jagani Z; Singh A; Khosravi-Far R
    Biochim Biophys Acta; 2008 Jan; 1785(1):63-84. PubMed ID: 17980712
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Forkhead transcription factor FOXO3a protein activates nuclear factor κB through B-cell lymphoma/leukemia 10 (BCL10) protein and promotes tumor cell survival in serum deprivation.
    Li Z; Zhang H; Chen Y; Fan L; Fang J
    J Biol Chem; 2012 May; 287(21):17737-17745. PubMed ID: 22474286
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
    Okabe S; Tauchi T; Katagiri S; Tanaka Y; Ohyashiki K
    J Hematol Oncol; 2014 Apr; 7():37. PubMed ID: 24775308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a.
    Buontempo F; Chiarini F; Bressanin D; Tabellini G; Melchionda F; Pession A; Fini M; Neri LM; McCubrey JA; Martelli AM
    Cell Cycle; 2012 Jul; 11(13):2467-75. PubMed ID: 22713244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
    Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
    Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-κB signaling.
    Rasheduzzaman M; Jeong JK; Park SY
    Life Sci; 2018 Sep; 208():208-220. PubMed ID: 30031063
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-kappaB.
    Grotterød I; Maelandsmo GM; Boye K
    BMC Cancer; 2010 May; 10():241. PubMed ID: 20507646
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway.
    Deeb D; Jiang H; Gao X; Al-Holou S; Danyluk AL; Dulchavsky SA; Gautam SC
    J Pharmacol Exp Ther; 2007 May; 321(2):616-25. PubMed ID: 17289836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
    Cooper MJ; Cox NJ; Zimmerman EI; Dewar BJ; Duncan JS; Whittle MC; Nguyen TA; Jones LS; Ghose Roy S; Smalley DM; Kuan PF; Richards KL; Christopherson RI; Jin J; Frye SV; Johnson GL; Baldwin AS; Graves LM
    PLoS One; 2013; 8(6):e66755. PubMed ID: 23826126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis.
    Kurosu T; Nagao T; Wu N; Oshikawa G; Miura O
    PLoS One; 2013; 8(11):e79478. PubMed ID: 24260231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.
    Gesbert F; Sellers WR; Signoretti S; Loda M; Griffin JD
    J Biol Chem; 2000 Dec; 275(50):39223-30. PubMed ID: 11010972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
    Gu JJ; Santiago L; Mitchell BS
    Blood; 2005 Apr; 105(8):3270-7. PubMed ID: 15604220
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
    Morinaga K; Yamauchi T; Kimura S; Maekawa T; Ueda T
    Int J Cancer; 2008 Jun; 122(11):2621-7. PubMed ID: 18338755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.
    Monteghirfo S; Tosetti F; Ambrosini C; Stigliani S; Pozzi S; Frassoni F; Fassina G; Soverini S; Albini A; Ferrari N
    Mol Cancer Ther; 2008 Sep; 7(9):2692-702. PubMed ID: 18790751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.